DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results.

VANCOUVER, British Columbia and MENLO PARK, Calif: DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended March 31, 2019. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on May 23, 2019 at 4:30 p.m. Eastern Time.

"The third quarter proved to be an important period of progress as we advanced VAL-083 in both of our Phase 2 clinical trials in GBM with encouraging early results, especially in our first line GBM trial, while continuing the evaluation of this first-in-class, small molecule's potential to treat a range of solid tumor cancers. I am also pleased by the establishment of our formal Scientific Advisory Board led by world-renowned oncology experts," commented Saiid Zarrabian, President and Chief Executive Officer of DelMar Pharmaceuticals. "In addition, we initiated execution of our planned rights offering to provide capital to continue the advancement of our clinical trials through their estimated planned completion in mid-calendar 2020, and we executed the necessary recent reverse stock split which potentially enables us to regain compliance with Nasdaq's listing requirements."

Key Highlights and Recent Developments

Achieved the halfway enrollment point for VAL-083's Phase 2, open-label, first-line temozolomide-naive, MGMT-unmethylated glioblastoma multiforme (GBM) study at Sun Yat-sen University Cancer Center (SYSUCC) with encouraging results for 11 of the initial 15 patients treated

Continued enrolling patients in VAL-083's Phase 2, open-label, second-line, Avastin-naive, MGMT-unmethylated, recurrent GBM study being conducted at the MD Anderson Cancer Center (MDACC)

Received approval from MDACC's Institutional Review Board (IRB) for protocol expansion to include maintenance stage, MGMT-unmethylated GBM patients. This provides an opportunity for enrollment of a larger patient population who may benefit from VAL-083 in an earlier stage of this hard-to-treat disease

Presented data supporting VAL-083 as potential treatment for pediatric brain tumors at the Society for Neuro-Oncology Pediatric Neuro-Oncology Basic and Translational Research Conference

Established Scientific Advisory Board with inaugural members Drs. Napoleone Ferrara and John de Groot

Potentially regained compliance with Nasdaq's minimum...